<DOC>
	<DOCNO>NCT00806338</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerance multiple intravenous ( vein ) dose trodusquemine ( MSI-1436 ) obese overweight , type 2 diabetic .</brief_summary>
	<brief_title>An Ascending Multi-Dose , Tolerance Pharmacokinetic Study Obese Overweight Type 2 Diabetic Volunteers</brief_title>
	<detailed_description>Different amount trodusquemine ( MSI-1436 ) give volunteer group throughout study . Another purpose evaluate pharmacokinetics ( PK - study way drug enters leave blood tissue time ) trodusquemine ( MSI-1436 ) . Finally , study also determine whether trodusquemine ( MSI-1436 ) effect appetite , mood behavior , selective biomarkers ( substance blood may change response study drug ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<criteria>1. male female obese overweight type 2 diabetic subject , 18 65 year old ( inclusive ) either treatment naïve inadequately control metformin alone ; 2. subject receive metformin stable dose least two week prior enrollment ; 3. fasting blood sugar ≥ 100 mg/dL hemoglobin A1C ≥ 7.5 % ( ≤ 11.0 % ) study entry ; 4. race good health ( base medical history , physical examination , electrocardiograms [ ECGs ] , clinical laboratory test ) ; 5. nonsmoker ( refrain tobacco nicotine usage , include smokeless tobacco , nicotine patch , etc. , ) 6 month prior Day 0 study . Subjects must cotinine level measure smoker base reference lab value ; 6. body mass index ( BMI ) 2740 kg/m2 ; 7. able execute inform write consent ; 8. willingness remain clinic inpatient portion study return followup visit require protocol deem necessary Principal Investigator ; 1. likely allergy sensitivity component Trodusquemine ( MSI1436C ) Injection ; 2. subject history severe allergy bronchial asthma ; 3. clinically significant history current abnormality disease organ system , include renal , hepatic , gastrointestinal , cardiovascular ( except hyperlipidemia control hypertension ) , pulmonary ( include chronic asthma ) , endocrine ( except diabetes ) , central nervous , hematologic system , recent clinically significant surgery ; 4. history seizure , epilepsy , severe head injury , multiple sclerosis , know neurological condition ; 5. abnormal preadmission vital sign , physical examination , clinical laboratory , safety variable consider clinically significant population Principal Investigator Sponsor ( designee ) . Subjects abnormal serum creatinine enrol . Subjects AST ( SGOT ) , ALT ( SGPT ) , GGT , alkaline phosphatase , bilirubin , blood urea nitrogen ( BUN ) , prothrombin time ( PT ) , activate partial thromboplastin time ( aPPT ) &gt; 1.5 time upper limit normal enrol ; 6. subject clinically significant mental physical illness within 1 year prior first dose , include history alcohol and/or drug abuse within 1 year prior first dose study medication ; 7 . Insulin require diabetic ; 8. subject receive known hepatic renal clearance alter agent ( eg , erythromycin , cimetidine , barbiturate , phenothiazine , St. John 's Wort , etc . ) within period 90 day prior first dose study medication ; 9. subject receive approved prescription antiobesity drug take overthecounter medication weight loss receive thiazolidinedione exanatide within period 90 day prior first dose study medication ; 10. ingestion use investigational medication device within 60 day prior first dose study medication ; ingestion use investigational antiobesity medication prohibit within 3 month prior first dose study medication ; 11. subject history malignancy last 5 year , exception basal squamous cell carcinoma skin ; 12. subject positive HBsAG , Hepatitis C antibody , Hepatitis A IgM , Human Immunodeficiency Virus ( HIV ) Viral Serology test screen visit ; 13. positive qualitative urine drug alcohol test screening checkin ; 14. mental capacity limit extent subject provide legal consent understand information regard study ; 15. subject 10 % weight loss past 3 month prior screen visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2009</verification_date>
</DOC>